Recent clinical trial data suggest a cardiorenal protective effect of sodium glucose
cotransporter 2 (SGLT2) inhibition. We demonstrate that chemical denervation in neurogenic …

Background: The sympathetic nervous system (SNS) regulates glucose metabolism in
various organs including the kidneys. The sodium glucose cotransporter 2 (SGLT2) …

Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …

Background: Recent clinical studies demonstrate that SGLT2 (sodium-glucose cotransporter
2) inhibitors ameliorate heart failure (HF). The present study was conducted to assess the …

Abstract Purpose of the Review Hyperactivity of sympathetic nervous system (SNS) plays a
role in the development of arterial hypertension and heart failure, two co-morbidities …

The kidney has a pivotal role in maintaining glucose homeostasis by using glucose as a
metabolic fuel, by producing glucose through gluconeogenesis, and by reabsorbing all …

Even in the presence of excess glucose, the proximal renal tubules continue to resorb more
glucose. Sodium glucose cotransporter 2 (SGLT2) inhibitors are drugs that control this …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Type 2 diabetes mellitus (T2DM) is a growing public health concern worldwide. Numerous
drug classes are available for treatment, however, their efficacy with regard to diabetes …

Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …